Journal of Medicinal Chemistry Corrections

Corrections to Structure−Activity Relationships of Antitubercular Nitroimidazoles. 2. Determinants of Aerobic Activity and Quantitative Structure−Activity Relationships [*J. Med. Chem.* **2009,** *52,* 1329. DOI: 10.1021/jm801374t]. Pilho Kim, Sunhee Kang, Helena I. Boshoff, Jan Jiricek, Margaret Collins, Ramandeep Singh, Ujjini H. Manjunatha, Pornwaratt Niyomrattanakit, Sejal Patel, Liang Zhang, Michael Goodwin, Thomas Dick, Thomas H. Keller, Cynthia S. Dowd,* and Clifton E. Barry, III*

Page 1329. An author was missing from the byline. The complete author listing is indicated above, and the complete listing with its associated affiliations is listed below:

Pilho Kim,[†] Sunhee Kang,[†,#] Helena I. Boshoff,[†] Jan Jiricek,[‡] Margaret Collins,[†] Ramandeep Singh,[†] Ujjini H. Manjunatha,[†,‡,¥] Pornwaratt Niyomrattanakit,[‡] Sejal Patel,[‡,×] Liang Zhang,[†,∥] Michael Goodwin,[†] Thomas Dick,[‡] Thomas H. Keller,[‡] Cynthia S. Dowd,*[,†,∞] and Clifton E. Barry, III*[,†]

*To whom correspondence should be addressed. For C.S.D.: phone, 202-994-8405; fax, 202-994-5873; e-mail, cdowd@gwu.edu. For C.E.B.: phone, 301-435-7509; fax, 301-480-5712; e-mail, cbarry@mail.nih.gov.

[†]National Institute of Allergy and Infectious Diseases.

[§]Present address: Korea Research Institute of Chemical Technology, Daejeon, Korea.

[#]Present address: Institut Pasteur Korea, Seoul, South Korea.

[‡]Novartis Institute for Tropical Diseases.

[¥]Present address: Novartis Institute for Tropical Diseases, Singapore.

[×]Present address: Novartis Institutes for BioMedical Research, Cambridge, MA.

[∥]Present address: Walter Reed Army Medical Hospital, Washington, DC.

[∞]Present address: Department of Chemistry, George Washington University, Washington, DC 20052.

DOI: 10.1021/jm901277v
Published on Web 09/01/2009

Corrections to Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) [*J. Med. Chem.* **2009,** *52,* 2255. DOI: 10.1021/jm801509w]. Dan Niculescu-Duvaz, Catherine Gaulon, Harmen P. Dijkstra, Ion Niculescu-Duvaz, Alfonso Zambon, Delphine Ménard, Bart M. J. M. Suijkerbuijk, Arnaud Nourry, Lawrence Davies, Helen Manne, Frank Friedlos, Lesley Ogilvie, Douglas Hedley, Steven Whittaker, Ruth Kirk, Adrian Gill, Richard D. Taylor, Florence I. Raynaud, Javier Moreno-Farre, Richard Marais, and Caroline J. Springer*

Page 2256. The authors have been notified by Plexxikon that the structure of PLX4032, published in *Expert Opin. Ther. Targets* **2007**, *11,* (12), 1587−1609 (Figure 4) and presented in p 2256, Figure 1, was incorrect and the correct one has not been released.

DOI: 10.1021/jm901076g
Published on Web 08/27/2009

Corrections to In Vitro Intrinsic Clearance-Based Optimization of N^3-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF_1) Receptor Antagonists [*J. Med. Chem.* **2009,** *52,* 4161. DOI: 10.1021/jm900302q]. Richard A. Hartz,* Vijay T. Ahuja, Maria Rafalski, William D. Schmitz, Allison B. Brenner, Derek J. Denhart, Jonathan L. Ditta, Jeffrey A. Deskus, Eddy W. Yue, Argyrios G. Arvanitis, Snjezana Lelas, Yu-Wen Li, Thaddeus F. Molski, Harvey Wong, James E. Grace, Kimberley A. Lentz, Jianqing Li, Nicholas J. Lodge, Robert Zaczek, Andrew P. Combs, Richard E. Olson, Ronald J. Mattson, Joanne J. Bronson, and John E. Macor

Pages 4161−4172. This is the second article in a back-to-back set of articles and should have been published immediately after, rather than before, this article: Hartz, R. A.; Ahuja, V. T.; Arvanitis, A. G.; Rafalski, M.; Yue, E. W.; Denhart, D. J.; Schmitz, W. D.; Ditta, J. L.; Deskus, J. A.; Brenner, A. B.; Hobbs, F. W.; Payne, J.; Lelas, S.; Li, Y.-W.; Molski, T. F.; Mattson, G. K.; Peng, Y.; Wong, H.; Grace, J. E.; Lentz, K. A.; Qian-Cutrone, J.; Zhuo, X.; Shu, Y.-Z.; Lodge, N. J.; Zaczek, R.; Combs, A. P.; Olson, R. E.; Bronson, J. J.; Mattson, R. J.; Macor, J. E. Synthesis, structure−activity relationships, and in vivo evaluation of N^3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF_1) receptor antagonists. *J. Med. Chem.* **2009**, *52,* 4173−4191.

Page 4172. The complete information for ref 31 is as follows: Hartz, R. A.; Ahuja, V. T.; Arvanitis, A. G.; Rafalski, M.; Yue, E. W.; Denhart, D. J.; Schmitz, W. D.; Ditta, J. L.; Deskus, J. A.; Brenner, A. B.; Hobbs, F. W.; Payne, J.; Lelas, S.; Li, Y.-W.; Molski, T. F.; Mattson, G. K.; Peng, Y.; Wong, H.; Grace, J. E.; Lentz, K. A.; Qian-Cutrone, J.; Zhuo, X.; Shu, Y.-Z.; Lodge, N. J.; Zaczek, R.; Combs, A. P.; Olson, R. E.; Bronson, J. J.; Mattson, R. J.; Macor, J. E. Synthesis, structure−activity relationships, and in vivo evaluation of N^3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF_1) receptor antagonists. *J. Med. Chem.* **2009**, *52,* 4173−4191.

DOI: 10.1021/jm9011033
Published on Web 08/26/2009